Company intelligence / Profile preview
Hemostemix Inc.
Calgary, Alberta, Canadahemostemix.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
In Phase II clinical trial for CLI, ACP-01 saved 93.5% of limbs. 83% of patients followed for up to 4.5 years showed improvement. The company is currently selling ACP-01 as treatment for CLI under exemption while advancing to Phase III trials.
- Therapeutic areas
- Cardiovascular
- Modalities
- Autologous cell therapyBlood-derived stem cell therapies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
CytoImmune Therapeutics
Beyond the preview
Go deeper on Hemostemix Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemostemix Inc..